Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

The Lancet

Published:

2025-09-18

DOI:

10.1016/s0140-6736(25)01774-x

Affiliations:

6

Authors:

8

Go to article

Institutions	Authors	Share
Lilly, United States of America (USA)	4.000000	0.50
Eli Lilly Services India Pvt Ltd, India	1.000000	0.13
Hospital Angeles Puebla, Mexico	1.000000	0.13
Indiana University Indianapolis (IU Indianapolis), United States of America (USA)	1.000000	0.13
USC Children's Hospital Los Angeles (CHLA), United States of America (USA)	0.500000	0.06
University of Southern California (USC), United States of America (USA)	0.500000	0.06

Interested in Clinical Sciences?